Addressing Anti-VEGF Durability Issues Through Novel Surgical Approaches for the Treatment of nAMD and DME

1.00 CME
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Addressing Anti-VEGF Durability Issues Through Novel Surgical Approaches for the Treatment of nAMD and DME


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Activity Description

Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the management paradigm for patients with retinal vascular diseases, yet there is still an unmet need to address treatment burden and loss of patient adherence due to dosing schedules. For patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), there is ongoing evaluation of gene therapy and surgical delivery devices with the potential to extend treatment intervals while maintaining visual acuity. These advances in treatment delivery require unique surgical approaches for optimal efficacy outcomes and safety. In this CME activity, experts in the field review the data on the recently approved Port Delivery System and emerging gene therapy approaches for managing nAMD and DME. Novel surgical techniques are reviewed, as well as clinical cases illustrating best practices for reducing potential surgical complications.

Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with retinal vascular diseases.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Recognize emerging surgical approaches that allow for the treatment of nAMD and DME over an extended period of time.
  • Evaluate novel surgical techniques and best practices that can reduce the potential for complications when using the port delivery system or subretinal gene therapy for nAMD or DME.

Activity Chair

Carl D. Regillo, MD, FACS
Director, Wills Eye Retina Service
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA


Margaret A. Chang, MD, MS
Senior Partner
Retinal Consultants of Sacramento
Sacramento, CA

Dilsher S. Dhoot, MD
Vitreoretinal Surgeon
California Retina Consultants
Santa Barbara, CA


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Medical Writer

Valerie Zimmerman, PhD

The articles in this monograph were composed by medical writer Valerie Zimmerman, PhD, based on the presentations of Drs. Chang, Dhoot, and Regillo during a live satellite symposium held on January 17, 2022. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn Continuing Certification credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, May 1, 2022, to May 1, 2023.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of 10 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relevant financial relationship(s)

Margaret A. Chang, MD, MS
Consultant: Genentech, Regenxbio
Independent Research Contractor: Allergan, Genentech, Novartis, Opthea, Regeneron, Regenxbio

Dilsher S. Dhoot, MD
Consultant: Alimera, Allergan, Apellis, Bayer, EyePoint, Genentech, Novartis, Regeneron
Speaker Contracted by Ineligible Company: EyePoint, Genentech, Novartis, Regeneron
Individual Stocks and Stock Options: Outlook Therapeutics, Vortex Surgical

Carl D. Regillo, MD, FACS
Consultant: Adverum, Allergan, Chengdu Kanghong, EyePoint, Genentech, Graybug, Kodiak, Novartis, Ocugen, Opthea
Independent Research Contractor: Adverum, Allergan, Chengdu Kanghong, EyePoint, Genentech, Graybug, Kodiak, Novartis, Opthea, Regeneron, Regenxbio

Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Medical Writer reports the following relevant financial relationship(s)

Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at